Outcomes after Stroke Thrombolysis According to Prior Antiplatelet Use. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Meseguer, Elena; Labreuche, Julien; Guidoux, Celine; Lavallée, Philippa C.; Cabrejo, Lucie; Sirimarco, Gaia; Valcarcel, Jaime G.; Klein, Isabelle F.; Amarenco, Pierre; Mazighi, Mikael
• Is Part Of: International journal of stroke. Volume 10:Issue 2(2015:Feb.)
• Page Start: 163
• Page End: 169
• Publication Date: 2015-02
• Subjects: antiplatelet -- aspirin -- ischemic stroke -- stroke -- thrombolysis -- tpa; 616.8005
• DOI: 10.1111/ijs.12421
• Languages: English
• ISSNs: 1747-4930

Abstract

Background: Thirty percent of ischemic stroke (IS) patients suffering from acute stroke are under antiplatelet therapy. Aims: We evaluated whether prior antiplatelet use before intravenous (IV), intra-arterial (IA) or combined IV/IA therapy may be associated with worse outcomes and an increased intracerebral hemorrhage (ICH) risk after reperfusion therapies. Methods: We analyzed data from our patient registry ( n = 874) and conducted a systematic review of previous observational studies. The primary outcome was the percentage of patients who developed symptomatic ICH (sICH), defined in our registry per ECASS-II definition. Results: We identified 43 previous reports that evaluated the impact of prior antiplatelet use on outcomes after reperfusion therapy in AIS patients. Prior antiplatelet use was found in 35% of AIS patients, eligible for reperfusion therapies and was associated with a worse vascular profile. In an unadjusted meta-analysis that included our registry data, prior antiplatelet use was associated with more sICH per ECASS-II definition (OR, 1·78 (95% CI, 1·48–2·13), and less favorable outcome (OR, 0·86; 95% CI, 0·77–0·98). However, in multivariate analyses conducted in our registry showed that prior antiplatelet use was not associated with worse outcome ( P > 0·23); and in the systematic review, only 3 studies reported a slight, but significant adjusted increase in sICH risk, of whom one had conflicting results according to sICH definition. Conclusions: These results suggest no significant detrimental effect of prior antiplatelet use in AIS patients treated by IV, IA or combined IV/IA therapy. Further studies are needed to assess the specific impact of different and cumulative antiplatelet agents.